Disease/Infection News

RSS

REGEN-COV shown to rapidly reduce SARS-CoV-2 viral load in hospitalized COVID-19 patients

Studies have shown that mortality rates in hospitalized patients with COVID-19 are high, ranging between 10% and 30%. REGEN-COV®, a combination of monoclonal antibodies casirivimab and imdevimab, is approved in the United States and other regions for emergency treatment of COVID-19 outpatients with mild to moderate SARS-CoV-2 infection and post-exposure prophylaxis.

10 Nov 2021

Surveillance approaches to monitor the presence of SARS-CoV-2 in a fully vaccinated population

Researchers at the University of Calgary Health Technology Assessment Unit investigated scientific evidence on various surveillance and testing methods to monitor the presence of the virus in a vaccinated population.

10 Nov 2021

Evidence that mild and even asymptomatic SARS-CoV-2 infection can lead to sustained immune activation

A paper published in the open-access journal Viruses, reports on a study investigating long-term changes to soluble inflammatory factors and cellular immune phenotype and function in 22 survivors of mild SARS-CoV-2 infection. The observations were then compared to 11 individuals who had recovered from other mild respiratory infections.

10 Nov 2021

Study tracks risk and protective behaviors related to transmission of HIV/AIDS in young adults

A number of behaviors in younger adults that increase risk for the transmission of HIV/AIDS have declined or changed between 2010 and 2020, according to the national Monitoring the Future study.

10 Nov 2021

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

A research group from the US (led by experts from Yale University School of Medicine) recently presented a case of an immunocompromised female patient with acquired deficiency of B lymphocytes who subsequently developed a protracted course of the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2021

ACTG announces launch of clinical trial evaluating a three-month TB treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB).

10 Nov 2021

Emergence of SARS-CoV-2 immune escape variants in an immunocompromised patient

A German case study recently published in the journal Nature Communications has characterized a long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dynamics in an immunosuppressed kidney transplant recipient and provided evidence for the evolution of SARS-CoV-2 into potentially harmful immune escape mutants during persistent infections.

10 Nov 2021

Risk of severe COVID-19 is rare among fully vaccinated individuals in England

A team of UK-based scientists has recently estimated the prevalence of vaccine breakthrough infections and severe disease in a large number of individuals fully vaccinated against coronavirus disease 2019 (COVID-19) in England.

10 Nov 2021

Global progress toward measles elimination continues to decline amidst the pandemic

While reported measles cases have fallen compared to previous years, progress toward measles elimination continues to decline and the risk of outbreaks is mounting, according to a new report from the World Health Organization and U.S. Centers for Disease Control and Prevention.

10 Nov 2021